Pulmonary Tuberculosis Clinical Trial
Official title:
Prokinetic Effect of Selected Nutraceuticals on Management of Gastrointestinal Disturbances Among Pulmonary Tuberculosis Patients
Verified date | December 2023 |
Source | Allama Iqbal Open University Islamabad |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Anti-Tuberculosis Treatment (ATT) is one of the effective treatments of tuberculosis but the use of drugs for a long time put an adverse effect on the gut and other organs of the body. Nutraceuticals are the cheapest natural sources with therapeutic effects. These natural medicines help in alleviating gastrointestinal disturbances. This study will be conducted to overcome gastrointestinal issues with the help of nutraceuticals, which are more acceptable by the majority and have no side effects.
Status | Completed |
Enrollment | 200 |
Est. completion date | March 15, 2022 |
Est. primary completion date | February 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Newly diagnosed Pulmonary TB patients (both genders) - Age group 18-65 years - Symptoms criteria (Rome IV) Exclusion Criteria: - Patients ? 18 years and ? 65 years. - Patients registered with extra pulmonary disease |
Country | Name | City | State |
---|---|---|---|
Pakistan | Sheikh Zayed Medical / college | Rahim Yar Khan | Punjab |
Lead Sponsor | Collaborator |
---|---|
Allama Iqbal Open University Islamabad |
Pakistan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | --GIT disturbances | GIT disturbences will be assessed through ROME IV including abdominal pain, bloating, vomiting and nausea in Phase 1. | "1 Month" at study commencement (Phase 1) | |
Primary | GIT disturbances | GIT disturbences will be assessed through ROME IV including abdominal pain, bloating, vomiting and nausea in Phase 2 after completion of three-month intervention. | Termination of Phase 2 (Intervention period) "3 Months" | |
Primary | GIT disturbances | GIT disturbences will be assessed through ROME IV including abdominal pain, bloating, vomiting and nausea in Phase 3 which is wash out time. | Termination of phase 3 (Washout period) "1 Month" | |
Secondary | Body Mass Index | Measurements will be taken in triplicate. Height will be measured to the nearest 0.5 cm with a stadiometer (or knee height, ulnar length or arm span [demispan] for those persons unable to stand fully erect); body weight will be measured to the nearest 0.1 kg. | "through study completion, an average of 9 months" | |
Secondary | A self-designed / pretested questionnaire | will be used to collect data on other determinants that affect patients regarding disease history, and dietary history. Agarwal Socio-economic status (SES) performa will be used. | "through study completion, an average of 9 months" | |
Secondary | Acid-Fast Bacillus (sputum) | sample will be taken at time of enrollment in study to make diagnosis of Tuberculosis | "through study completion, an average of 9 months" | |
Secondary | Chest X-ray (CXR) | Phase 1 in which subjects will be enrolled and their CXR will be taken as criteria for diagnosis of TB | "1 Day" at study commencement (Phase 1) | |
Secondary | Complete blood count (CBC) | Phase 1 in which subjects will be enrolled and their CBC will be taken as criteria for diagnosis of TB | "1 Day" at study commencement (Phase 1) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02736864 -
Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae
|
N/A | |
Not yet recruiting |
NCT04055441 -
A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital
|
||
Completed |
NCT02349841 -
Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis
|
Phase 2 | |
Completed |
NCT01927159 -
Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT01691534 -
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
|
Phase 2 | |
Completed |
NCT00803322 -
Improving Community Based Tuberculosis Care in Ethiopia
|
Phase 4 | |
Completed |
NCT00834353 -
Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis
|
N/A | |
Withdrawn |
NCT03277742 -
Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz
|
N/A | |
Completed |
NCT00057434 -
Vitamin A Therapy for Tuberculosis
|
Phase 3 | |
Not yet recruiting |
NCT06192160 -
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
|
Phase 2 | |
Recruiting |
NCT06127641 -
Rehabilitation of People With Post-tuberculosis Lung Disease
|
N/A | |
Recruiting |
NCT06058299 -
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
|
Phase 2 | |
Completed |
NCT04550832 -
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
|
Phase 2 | |
Completed |
NCT02912832 -
Prospective Assessment of TBDx Feasibility
|
N/A | |
Completed |
NCT01215851 -
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z)
|
Phase 2 | |
Recruiting |
NCT01503099 -
Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease
|
N/A | |
Completed |
NCT04608955 -
Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081
|
Phase 2 | |
Recruiting |
NCT05046366 -
Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
|
||
Completed |
NCT05896930 -
Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
|
Phase 2 | |
Completed |
NCT02279875 -
A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)
|
Phase 2 |